<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161940</url>
  </required_header>
  <id_info>
    <org_study_id>090-04</org_study_id>
    <nct_id>NCT01161940</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions</brief_title>
  <official_title>A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories
      Limited under fasting conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-period, two sequence, single dose,
      crossover, comparative oral bioavailability study in healthy, adult, male human subjects
      under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nizatidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Axid 300 mg Capsules of Reliant Pharmaceuticals, US</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nizatidine</intervention_name>
    <description>Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited</description>
    <arm_group_label>Nizatidine</arm_group_label>
    <other_name>Axid 300 mg Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axid</intervention_name>
    <description>Axid 300 mg Capsules of Reliant Pharmaceuticals, US</description>
    <arm_group_label>Axid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males between 18 and 55 years of age (inclusive) living in and around
             Ahmedabad city of western part of India.

          -  Having a Body Mass Index (BMI) ≥ 18.0 kg/m2 (calculated as weight in kg/ height in
             m2).

          -  Have no significant diseases or clinically significant abnormal findings during
             screening, medical history, physical examination, laboratory evaluations, ECG and
             X-ray recordings.

          -  Able to communicate effectively with study personnel. Able to give consent for
             participation in the trial

        Exclusion Criteria:

          -  Known hypersensitivity or idiosyncratic reaction to nizatidine or other related drugs.

          -  Any disease or condition which might compromise the haemopoietic, renal, hepatic,
             endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological,
             gastrointestinal, or any other body system.

          -  Ingestion of a medication at any time in 14 days before the start of the study. In any
             such case subject selection will be at the discretion of the Principal
             Investigator/Medical expert/co-investigator.

          -  Any history or presence of asthma or nasal polyp.

          -  A recent history of alcoholism (&lt;2years) or of moderate (180 ml/day) alcohol use.

          -  Smokers, who smoke more than 10 cigarettes/day or those who cannot refrain from
             smoking during study period.

          -  The presence of clinically significant abnormal laboratory values during screening.

          -  Use of any recreational drugs or history of drug addiction or testing positive in
             pre-study drug scan.

          -  History of psychiatric disorders.

          -  A history of difficulty with donating blood.

          -  Donations of blood (1 unit or 450 ml) within 90 days prior to receiving the first dose
             of study medication. Note: Incase the blood loss is ≤ 200 L, subject may be dosed
             after completion of 60 days of blood donation).

          -  A positive hepatitis screen including hepatitis B surface antigen, anti-HCV and
             anti-HAV antibodies.

          -  A positive test result for HIV antibody and/or syphilis.

          -  The receipt of an investigational product or participation in a drug research study
             within a period of 90 days prior to the first dose of study medication (Elimination
             half-life of the study drug should be taken into consideration for inclusion of the
             subject in the study). (Note: If subject had participated in a study in which blood
             loss is ≤200 mL, subject can be dosed after completion of 60 days of previous study).

          -  An unusual diet, for whatever reason (eg., low-sodium), for four weeks prior to
             receiving the study medication and throughout the subjects, participation in the
             study. In any such case subject will be at the discretion of the Principal
             Investigator/Medical expert/Co-investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charu Gautam, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>July 13, 2010</last_update_submitted>
  <last_update_submitted_qc>July 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>vice President, Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Nizatidine</keyword>
  <keyword>Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nizatidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

